Latest Élan Stories
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI(R) (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval.
DUBLIN, Ireland, July 18, 2008 (PRIME NEWSWIRE) -- Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk.
Elan and Wyeth have announced positive preliminary findings from a Phase II study of bapineuzumab in patients with mild to moderate Alzheimer's disease. In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's disease.
The much anticipated results of a clinical trial of one of the more promising Alzheimer's drugs, released June 17, were mixed at best. But in the Alzheimer's world that qualifies as a success -- and on Wall Street, it was a winner as well. Wyeth Pharmaceuticals (WYE) and Elan Corp.
By Michael Smith DUBLIN (Reuters) - Elan Corp. Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri showed significant positive results in patients, sending its shares higher.
DUBLIN (Reuters) - Elan Corporation Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri on sufferers showed significant positive effects on their quality of life.
By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A panel of independent experts on Wednesday unanimously urged the U.S. return of Biogen Idec's multiple sclerosis drug Tysabri, a medicine abruptly pulled from the market last year after it was linked to a life-threatening side effect.
By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri can return to the market as long as there are safeguards to closely monitor patients for a life-threatening side effect, a U.S. advisory panel unanimously said on Wednesday.
GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan Corp.'s Tysabri multiple sclerosis drug should return to the U.S. market, an advisory panel recommended on Wednesday. Tysabri sales were suspended in February 2005 after three patients developed a serious brain and spinal cord infection.
GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.